Alterations in EGFR, KRAS, and ALK are oncogenic drivers in lung cancer, but how oncogenic signaling influences immunity in the tumor microenvironment is just beginning to be understood. Immunosuppression likely contributes to lung cancer, because drugs that inhibit immune checkpoints like PD-1 and PD-L1 have clinical benefit. Here, we show that activation of the AKT/mTOR pathway tightly regulates PD-L1 expression in vitro and in vivo. Both oncogenic and IFN-γ-mediated induction of PD-L1 was dependent on mTOR. In human lung adenocarcinomas and squamous cell carcinomas, membranous expression of PD-L1 was significantly associated with mTOR activation. These data suggest oncogenic activation of the AKT/mTOR pathway promotes immune escape by driving expression of PD-L1, which was confirmed in syngeneic and genetically engineered mouse models of lung cancer where an mTOR inhibitor combined with a PD-1 antibody decreased tumor growth, increased tumor-infiltrating T cells, and decreased regulatory T cells.
Introduction
Despite the development of targeted therapies, lung cancer remains the leading cause of cancer-related death worldwide (1) . Most of the oncogenic drivers in non-small cell lung cancer (NSCLC), such as EGFR or KRAS, activate the PI3K/AKT/mTOR pathway, which increases cell proliferation, metabolism and survival. Activation of this pathway is a critical event during lung tumorigenesis.
Previously, we showed that genetic deletion of AKT1 or inhibitors of mTOR such as rapamycin or metformin prevent KRAS-driven lung tumorigenesis (2) (3) (4) . We also demonstrated a relationship between AKT/mTOR signaling and immune suppression, because inhibition of tumorigenesis by rapamycin was associated with reduced influx of lung associated FoxP3 + regulatory T cells (Tregs) into the tumors (5) . This was confirmed by creating mice that harbored mutant KRAS but lacked Although multiple mechanisms can contribute to immune suppression in the tumor microenvironment, programmed death ligand 1 (PD-L1, B7-H1), an inhibitory member of the B7 family, plays a central role in many cancer types (6) .
This cell surface protein is normally found on immune cells and in immune privileged tissues, but its expression is upregulated in many epithelial tumors including lung cancer (7) . PD-L1 binds to either PD-1 or CD80 receptors on activated immune cells to inhibit their activation and effector responses (8) . The interaction of PD-L1 and PD-1 induces differentiation of naïve CD4 + T cells into Tregs and maintains Treg suppressive functions. PD-L1 can also act as a receptor by sending reverse signals to limit tumor cell apoptosis. The importance of PD-L1 and PD-1 in lung cancer is reflected by the anti-tumor activity observed using PD-1 or PD-L1 blocking antibodies as single agents in heavily pretreated NSCLC patients (9, 10) . Clinical responses were sometimes sustained over many months, suggesting recovered ability of immune effectors to control tumor growth (11) . This clinical benefit supports efforts to study the mechanisms that regulate tumor PD-L1 expression and therapeutic interventions to decrease PD-L1 levels.
Tumors can express PD-L1 either constitutively or through induction by inflammatory cytokines, especially members of the interferon family. Cytokinedriven PD-L1 expression is indicative of an ongoing immune response in the tumor microenvironment, while intrinsic PD-L1 expression does not depend on the presence of tumor-infiltrating lymphocytes.
Multiple mechanisms can contribute to intrinsic tumor PD-L1 expression.
Expression of PD-L1 and PD-L2 (another ligand for PD-1) are increased in Hodgkin's disease and mediastinal large B-cell lymphoma through chromosomal amplification (12) . T cell lymphomas carrying NPM/ALK fusions induce PD-L1 expression through STAT3 activation (13) . PTEN loss or PIK3CA mutations in glioma, breast and prostate cancers have been shown to activate the AKT/mTOR pathway and subsequently increase PD-L1 expression (14, 15) . A correlation between activating mutations in EGFR and increased immunosuppression markers, including PD-L1
and PD-1, was established (16 (17) . In NSCLC patients, the relationship of oncogenic drivers with PD-L1 expression is still unclear with one study associating PD-L1 expression with mutant EGFR but not KRAS or ALK (18) , and another demonstrating no clear difference in PD-L1 staining between samples with mutations in EGFR, KRAS or ALK (19) . Since the AKT/mTOR pathway serves as a convergence point for activation of many of the oncogenes involved in NSCLC, we hypothesized that this pathway was likely responsible for the control of PD-L1 expression. We used NSCLC cell lines, mouse models and primary human lung cancers to show that PD-L1 protein expression is dependent on active AKT/mTOR signaling, regardless of specific oncogenic or cytokine stimuli. These data identify a common mechanism of PD-L1 regulation in lung cancer, and provided rationale for clinical trials of oncogenic pathway inhibitors combined with inhibitors of immune checkpoints. were passaged for fewer than 6 months after resuscitation.
Material and Methods

Cell
Transfections. CL13 cells were transfected with DharmaFECT (Thermo Scientific) and a pool of 4 mouse PTEN siRNA or scrambled siRNA (L-040700-00-0005, Thermo Scientific). The pLKO.1 plasmid containing shRNA targeted to human RAPTOR or RICTOR have been described previously (22) .
Mouse Models. All animal studies were conducted using a protocol approved by the Animal Care and Use Committee at the National Cancer Institute. The genetically engineered KRAS LA2 and CC10 + EGFR L585R/T790M mice, as well as, the NNK-induced A/J mouse lung tumor model have been described previously (3, 23, 24) .
In vivo treatments. For the transgenic KRAS LA2 mouse model treatment began at weaning and lasted 4wks. 150 μg of anti-PD-1 blocking antibody (Amplimmune) was given on the first treatment day in combination with rapamycin. Control vehicle and was given on treatment day 1 in combination with 150 μg IgG (Rockland). A previously optimized rapamycin dosing schedule was used to obtain trough levels that are readily tolerated in humans (25) . The control and anti-PD-1 antibody were given by intraperitoneal injection (IP) once a week for 3wksand tumors were harvested 1hr after the last injection. Mice were weighed QOD to monitor for toxicity. Tumor burden was calculated as the sum of individual lung tumor volumes per mouse. TMA slides were stained with the 5H1 antibody for PD-L1 expression and a mouse IgG isotype antibody using a previously described protocol by a board certified pathologist (QKL) (26) . Approximately 10% of randomly chosen cores were scored to confirm PD-L1 by a second board certified pathologist (JT). Both TMAs were also analyzed for pS6 S235/236 (CST#4858) expression. Tumor with >10% phospho-S6 expression were considered positive.
Statistical Analysis. Data in bar graphs are presented as mean ± standard error.
Chi-square analyses tested for differences between the distributions of clinical variables across histologic samples. The Fisher's exact test examined potential statistical associations of the association between PD-L1 and phospho-S6 expression in both TMAs. Quantification of immunoblotting was analyzed by unpaired student t test. Tumor volume and tumor-infiltrating lymphocytes were analyzed by two-way ANOVA followed by Tukey's post hoc test. Statistical significance was reached with a p value less than or equal to 0.05. Similarly, lung tumors from KRAS LA2 mice treated for 10 weeks with rapamycin also had lower PD-L1 expression and mTOR activation compared to vehicle-treated littermates ( Figure 3B ). Six weeks after doxycycline administration mutant EGFR L858R/T790M mice were treated for 1 week with vehicle or rapamycin. Lung tumors from mice treated with rapamycin had reduced mTOR activation and PD-L1 expression compared to vehicle-treated mice ( Figure 3C ). These studies indicate that mTOR activation is correlated with PD-L1 expression in murine lung tumors. To explore the potential regulation of PD-L1 in human primary lung tumors by mTOR activation, both TMAs were also stained with an antibody specific for phosphorylation of S6 at S235/236 (Supplementary Figure 3C-D) . Since there were no significant differences between the TMA characteristics (Supplemental Table 1; stage significance is likely due to a sample size bias), the adenocarcinomas and squamous cell carcinomas were combined for further analyses. Approximately 90% of tumors with PD-L1 expression had activation of mTOR and 54% of tumors with mTOR activation also expressed PD-L1 suggesting that mTOR activation was necessary, but not sufficient, for PD-L1 expression ( Table 1) . Distribution of mTOR activation tended to be similar to staining patterns for PD-L1, suggesting the same cells co-express both markers (Supplementary Figure 4) . The majority (83%) of tumors negative for pS6 were also negative for PD-L1. A small subset of tumors expressed PD-L1 without mTOR activation, indicating there may be additional mechanisms inducing PD-L1 expression. 63/158 (40%) of lung tumors had both active mTOR signaling and PD-L1 expression, and a Fisher's exact test revealed a statistically significant correlation between the two markers (p=0.0001) ( Table 1) .
Results
Expression of PD-L1 in mutant EGFR
Activation of the AKT/mTOR pathway increases PD-L1 expression
These results underscore the clinical relevance of our preclinical associations. Implementing rapamycin as a cancer therapy raises issues about its own role in immunosuppression. Rapamycin has a black box warning from the Food and Drug Administration stemming from a study of renal transplant patients who were also taking cyclosporine and corticosteroids (47) , but multiple trials of single-agent rapamycin or rapamycin-analogues in cancer patients have shown no evidence of increased incidence of immunosuppression (25, 48) . In fact, many basic and clinical studies have associated rapamycin with active immune responses (49, 50 
